SCN1A testing can be done through bi-directional DNA sequencing and multiplex ligation-dependent probe amplification (MLPA) for:1) individuals with electroclinical phenotype of Dravet Syndrome or clinical sub-types – several seizure types in one individual with onset in infancy, refractory to medication and with generalised spike and wave on EEG, or2) infants less than 1 year old with 2 or more prolonged hemiclonic febrile seizures in early infancy.Disclaimer: This summary is based on a UK Genetic Testing Network (UKGTN) approved Gene Dossier application. Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.